HY-071221

HY-071221 is a potent and selective small molecule inhibitor of Tyrosine Kinase 2 (TYK2), currently under development by Hefei Yigong Pharmaceutical for the treatment of systemic lupus erythematosus (SLE). TYK2 is a member of the Janus kinase (JAK) family that plays a critical role in the signaling pathways of cytokines such as Type I interferons, IL-12, and IL-23, which are central to the pathogenesis of SLE. By selectively targeting the TYK2 enzyme, HY-071221 aims to suppress the inflammatory response while minimizing the off-target effects typically associated with non-selective JAK inhibitors. The candidate is currently being evaluated in Phase 2 clinical trials in China to assess its safety and efficacy in patients with active SLE.